Silencing of the scavenger receptor (Class B - Type 1) gene using siRNA-loaded chitosan nanaoparticles in a HepG2 cell model

Colloids and Surfaces B: Biointerfaces

Volumn 123, Issue , 2014, Pages 930-937

  Farid, Mariane M ^a   Hathout, Rania M ^a,b   Fawzy, Mahmoud ^a   Abou Aisha, Khaled ^a  

^a German University in Cairo   (Egypt)

^b Ain Shams University   (Egypt)

Author keywords

Chitosan nanoparticles; HCV; Scavenger receptor; SiRNA; SR B1

Indexed keywords

CELL CULTURE; CELLS; CROSSLINKING; ELECTROPHORESIS; GELATION; GENES; NANOPARTICLES; PARTICLE SIZE; VIRUSES;

CHITOSAN NANOPARTICLES; HCV; NANOPARTICLE UPTAKES; SCAVENGER RECEPTOR; SIRNA; SMALL INTERFERING RNA (SIRNA); SODIUM TRIPOLYPHOSPHATE; WESTERN-BLOT ANALYSIS;

CHITOSAN;

CHITOSAN; CHITOSAN NANOPARTICLE; FLUORESCEIN ISOTHIOCYANATE; NANOPARTICLE; SCAVENGER RECEPTOR BI; SMALL INTERFERING RNA; TRIPOLYPHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; CELL TRANSPORT; CELLULAR DISTRIBUTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; GELATION; GENE SILENCING; HEPATITIS C VIRUS; HEPG2 CELL LINE; PARTICLE SIZE; SR B1 GENE; VIRUS ENTRY; WESTERN BLOTTING;

HEPATITIS C VIRUS;

EID: 84915793430     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2014.10.045     Document Type: Article

References (48)

1. Pinto R.C., Neufeld R.J., Ribeiro A.J., Veiga F., Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2006, 2:8-21.
2. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 2001, 70:1-20.
3. Singh R., Lillard J.W. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 2009, 86:215-223.
4. Akinc A., Thomas M., Klibanov A.M., Langer R. Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J. Gene Med. 2005, 7:657-663.
5. Desai M.P., Labhasetwar V., Walter E., Levy R.J., Amidon G.L. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. 1997, 14:1568-1573.
6. Ojea-Jimenez I., Tort O., Lorenzo J., Puntes V.F. Engineered nonviral nanocarriers for intracellular gene delivery applications. Biomed. Mater. 2012, 7:054106.
7. Catanese M.T., Ansuini H., Graziani R., Huby T., Moreau M., Ball J.K., Paonessa G., Rice C.M., Cortese R., Vitelli A., Nicosia A. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J. Virol. 2010, 84:34-43.
8. Bansal V., Sharma P.K., Sharma N., Pal O.P., Malviya R. Applications of chitosan and chitosan derivatives in drug delivery. Adv. Biol. Res. 2011, 5:28-37.
9. Ozpolat B., Sood A.K., Lopez-Berestein G. Nanomedicine based approaches for the delivery of SiRNA in cancer. J. Intern. Med. 2010, 267:44-53.
10. Gan Q., Wang T., Cochrane C., McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloids Surf. B: Biointerfaces 2005, 44:65-73.
11. Reaven E., Cortez Y., Leers-Sucheta S., Nomoto A., Azhar S. Dimerization of the scavenger receptor class B type I formation, function, and localization in diverse cells and tissues. J. Lipid Res. 2004, 45:513-528.
12. Scarselli E., Ansuini H., Cerino R., Roccasecca R.M., Acali S., Filocamo G., Traboni C., Nicosia A., Cortese R., Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 2002, 21:5017-5025.
13. Voisset C., Callens N., Blanchard E., Op De B.A., Dubuisson J., Vu-Dac N. High density lipoproteins facilitate hepatitis C Virus Entry through the scavenger receptor class B type I. J Biol. Chem. 2005, 280:7793-7799.
14. Abdel-Hafez S.M., Hathout R.M., Sammour O.A. Toward better modeling of chitosan nanoparticles production: screening different factors and comparing two experimental designs. Int. J Biol. Macromol. 2014, 64:334-340.
15. Calvo P., Remunan-Lopez C., Vila-Jato J.L., Alonso M.J. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J. Appl. Polym. Sci. 1997, 63:125-132.
16. Santa Cruz 2013, http://datasheets.scbt.com/siRNA_protocol.pdf (internet).
17. Katas H., Alpar H.O. Development and characterisation of chitosan nanoparticles for SiRNA delivery. J. Control. Release 2006, 115:216-225.
18. Seipp S., Mueller H.M., Pfaff E., Stremmel W., Theilmann L., Goeser T. Establishment of persistent hepatitis C virus infection and replication in vitro. J. Gen. Virol. 1997, 78:2467-2476.
19. Mehrotra A., Nagarwal R.C., Pandit J.K. Lomustine loaded chitosan nanoparticles: characterization and in-vitro cytotoxicity on human lung cancer cell line L132. Chem. Pharm. Bull. (Tokyo) 2011, 59:315-320.
20. Zhou H., Yang L., Li H., Gong H., Cheng L., Zheng H., Zhang L.M., Lan Y. Downregulation of VEGF MRNA expression by triamcinolone acetonide acetate-loaded chitosan derivative nanoparticles in human retinal pigment epithelial cells. Int. J. Nanomed. 2012, 7:4649-4660.
21. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
22. Reaven E., Cortez Y., Leers-Sucheta S., Nomoto A., Azhar S. Dimerization of the scavenger receptor class B type I: formation, function, and localization in diverse cells and tissues. J. Lipid Res. 2004, 45:513-528.
23. Schroeder A., Levins C.G., Cortez C., Langer R., Anderson D.G. Lipid-based nanotherapeutics for SiRNA delivery. J. Intern. Med. 2010, 267:9-21.
24. Gref R., Domb A., Quellec P., Blunk T., Müller R.H., Verbavatz J.M., Langer R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev. 1995, 16:215-233.
25. Malmo J., Sorgard H., Varum K.M., Strand S.P. SiRNA delivery with chitosan nanoparticles: molecular properties favoring efficient gene silencing. J. Control. Release 2012, 158:261-268.
26. Mao S., Sun W., Kissel T. Chitosan-based formulations for delivery of DNA and SiRNA. Adv. Drug Deliv. Rev. 2010, 62:12-27.
27. Rozema D.B., Lewis D.L. SiRNA delivery technologies for mammalian systems. Targets 2003, 2:253-260.
28. Lu J.J., Langer R., Chen J. A novel mechanism is involved in cationic lipid-mediated functional SiRNA delivery. Mol. Pharm. 2009, 6:763-771.
29. Alameh M., Dejesus D., Jean M., Darras V., Thibault M., Lavertu M., Buschmann M.D., Merzouki A. Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery. Int. J. Nanomed. 2012, 7:1399-1414.
30. Csaba N., Koeping-Hoeggard M., Jose Alonso M. Ionically crosslinked chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery. Int. J. Pharm. 2009, 382:205-214.
31. Mitra R.N., Han Z., Merwin M., Al T.M., Conley S.M., Naash M.I. Synthesis and characterization of glycol chitosan DNA nanoparticles for retinal gene delivery. ChemMedChem. 2013.
32. Molinaro R., Wolfram J., Federico C., Cilurzo F., Di M.L., Ventura C.A., Carafa M., Celia C., Fresta M. Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors. Expert Opin. Drug Deliv. 2013, 10:1653-1668.
33. Bivas-Benita M., Romeijn S., Junginger H.E., Borchard G. PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium. Eur. J. Pharm. Biopharm. 2004, 58:1-6.
34. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2012.
35. Zauner W., Farrow N.A., Haines A.M. In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density. J. Control. Release 2001, 71:39-51.
36. Faraji A.H., Wipf P. Nanoparticles in cellular drug delivery. Bioorganic Med. Chem. 2009, 17:2950-2962.
37. Shu X.Z., Zhu K.J. The Influence of multivalent phosphate structure on the properties of ionically cross-linked chitosan films for controlled drug release. Eur. J. Pharm. Biopharm. 2002, 54:235-243.
38. Wang J.J., Zeng Z.W., Xiao R.Z., Xie T., Zhou G.L., Zhan X.R., Wang S.L. Recent advances of chitosan nanoparticles as drug carriers. Int. J. Nanomed. 2011, 6:765-774.
39. Ali S.W., Joshi M., Rajendran S. Synthesis and characterization of chitosan nanoparticles with enhanced antimicrobial activity. Int. J. Nanosci. 2011, 10:979-984.
40. Bulmer C., Margaritis A., Xenocostas A. Production and characterization of novel chitosan nanoparticles for controlled release of RHu-erythropoietin. Biochem. Eng. J. 2012, 68:61-69.
41. Yang H.C., Hon M.H. The effect of the molecular weight of chitosan nanoparticles and its application on drug delivery. Microchem. J. 2009, 92:87-91.
42. Huang M., Fong C.W., Khor E., Lim L.Y. Transfection efficiency of chitosan vectors: effect of polymer molecular weight and degree of deacetylation. J. Control. Release 2005, 106:391-406.
43. Fan W., Yan W., Xu Z., Ni H. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf. B: Biointerfaces 2012, 90:21-27.
44. Rhainds D., Falstrault L., Tremblay C., Brissette L. Uptake and fate of Class B scavenger receptor ligands in HepG2 cells. Eur. J. Biochem. 1999, 261:227-235.
45. Buckwold V.E., Collins B., Hogan P., Rippeon S., Wei J. Investigation into the Ability of GB Virus B to replicate in various immortalized cell lines. Antivir. Res. 2005, 66:165-168.
46. Triyatni M., Saunier B., Maruvada P., Davis A.R., Ulianich L., Heller T., Patel A., Kohn L.D., Liang T.J. Interaction of Hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J. Virol. 2002, 76:9335-9344.
47. Santa Cruz 2013, http://datasheets.scbt.com/sc-44752.pdf.
48. Catanese M.T., Graziani R., von H.T., Moreau M., Huby T., Paonessa G., Santini C., Luzzago A., Rice C.M., Cortese R., Vitelli A., Nicosia A. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J. Virol. 2007, 81:8063-8071.